Luc Tanguay
No más puestos en curso
Perfil
Luc Tanguay served as the President, CEO & Non-Independent Director of Theratechnologies, Inc. from 2012 to 2020.
Prior to that, he was a Director at Ambrilia Biopharma, Inc. from 2006 to 2010.
He also served as the Chairman of Valeo Management LP.
Tanguay received his undergraduate and graduate degrees from the University of Sherbrooke.
Antiguos cargos conocidos de Luc Tanguay.
| Empresas | Cargo | Fin |
|---|---|---|
| THERATECHNOLOGIES INC. | Director Ejecutivo | 06/04/2020 |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Director/Miembro de la Junta | 31/03/2010 |
Valeo Management LP
 Valeo Management LP Miscellaneous Commercial ServicesCommercial Services Valeo Management LP offers research commercialization services. The firm provides Life sciences and biotechnologies, engineering, information and communications technologies services. The company was founded in 2000 and is headquartered in Montreal, Canada. | Presidente | - |
Formación de Luc Tanguay.
| University of Sherbrooke | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Valeo Management LP
Valeo Management LP Miscellaneous Commercial ServicesCommercial Services Valeo Management LP offers research commercialization services. The firm provides Life sciences and biotechnologies, engineering, information and communications technologies services. The company was founded in 2000 and is headquartered in Montreal, Canada. | Commercial Services |
- Bolsa de valores
- Insiders
- Luc Tanguay
